Invention Grant
- Patent Title: Anti-OX40 antibodies and methods of activating OX40
-
Application No.: US16635806Application Date: 2018-08-01
-
Publication No.: US11242398B2Publication Date: 2022-02-08
- Inventor: Frank J Calzone , Hai Yan , John Zhang
- Applicant: REMD Biotherapeutics, Inc.
- Applicant Address: US CA Camarillo
- Assignee: REMD Biotherapeutics, Inc.
- Current Assignee: REMD Biotherapeutics, Inc.
- Current Assignee Address: US CA Camarillo
- Agency: Craig A Crandall, APC
- Agent Craig A Crandall
- International Application: PCT/US2018/044882 WO 20180801
- International Announcement: WO2019/028182 WO 20190207
- Main IPC: C07K16/18
- IPC: C07K16/18 ; A61K39/395 ; C07K16/28
Abstract:
This application provides, inter alia, antibodies or antigen-binding fragments thereof, targeting OX40 expressed on injured tissues associated with multiple diseases. These OX40 antibodies, or antigen-binding fragments thereof, have a high affinity for OX40 and function as OX40 agonists or as OX40/OX40L antagonists. The antibodies and antigen-binding fragments are useful for treatment of human diseases, infections, and other conditions.
Public/Granted literature
- US20210024640A1 CANCER TREATMENT USING ANTIBODIES THAT BIND HUMAN CD134 (OX40) RECEPTOR Public/Granted day:2021-01-28
Information query
